Use of tegaserod in preparation of anti-tumor drug
US12364682B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 17, 2020 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | Aug 9, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure discloses the use of Tegaserod or a pharmaceutically acceptable salt thereof as a JAK-STAT3 signaling pathway inhibitor and an immunomodulator in the preparation of an anti-tumor drug. Tegaserod and the pharmaceutically acceptable salt thereof show a very excellent inhibitory effect on the growth of various tumor cells in vivo and in vitro, and are expected to be used in the treatment of various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.